OptimizeRx Corporation (OPRX) Earnings Call Transcript
August 12, 2026
Earnings Call Speaker Segments
Thanks, operator, and good afternoon to all of you. We appreciate your presence on our call covering the second quarter of 26. We're happy to share that Q2 revenue came in at $20.5 million, with adjusted EBITDA reaching $4.9 million — each figure surpassing what consensus had anticipated. What these numbers show is ongoing margin improvement, careful operational discipline, and the durability of our operating model, even as the health care marketing landscape stays dynamic. Revenue did fall compared to the same period a year ago, and contracted revenue is still under where it stood in the prior year. However, those decreases are confined to a handful of large customers — among them the 1 customer we mentioned on last quarter's call, which once again produced no revenue this quarter — along with customers who leaned more heavily in earlier years on lower margin managed service offerings, areas we've been moving away from since acquiring Medicx in 2023. Beyond those few customers, and throughout the rest of the business, we're encouraged by strengthening engagement and growth. Meanwhile, our ongoing investment in platform capabilities — such as recent product launches and broader programmatic initiatives — is bolstering customer engagement and reinforcing our competitive position as we enter the 2027 planning cycle. Even though the timing and mix of second half revenue carries some variability, our first half performance, promising commercial momentum, and present outlook back our choice to reaffirm full year 2026 revenue guidance between $95 million and $100 million, along with adjusted EBITDA guidance between $21 million and $25 million. Edward will share more specifics during his prepared remarks. For the last several quarters, we've kept our attention on executing the initiatives within our control: boosting profitability, reinforcing our balance sheet, broadening our technology platform, and opening new paths for long term growth. In my view, our second quarter results show the progress achieved on each of those priorities. Even as parts of the pharmaceutical marketing landscape keep encountering budget timing variability and cautious spending behavior, we take encouragement from the ongoing stabilization we observe among many of our largest customers. Even more significantly, the long term secular trends propelling our business stay solidly in place. Life science organizations keep moving toward engagement that is more measurable and data driven, delivering value where clinical decisions are made. Healthcare marketers increasingly look for AI enabled planning, authenticated health care audiences, measurable outcomes, and seamless programmatic execution; these are exactly the areas where OptimizeRx has invested for years, and where we think we hold a meaningful competitive advantage. Our existing customers keep broadening their use of our platform across additional brands, therapeutic areas, and commercial use cases. During the quarter, we saw continued adoption of our AI enabled audience activation platform, or DAP, which rose over 30% year-over-year. At the same time, we expanded our point-of-prescribe capabilities across both pharmaceutical and med tech customers. These solutions are powered by OptimizeRx's proprietary foundational data asset, which keeps growing as more engagement transpires across our ecosystem. We're also still gaining ground when it comes to growing our presence with life science organizations that are mid sized and emerging, and in our view these represent 1 of the biggest opportunities still untapped inside our commercial business. As more of these organizations look for technology at enterprise grade without having to take on enterprise scale or make infrastructure investments, we think our platform holds a uniquely strong position to satisfy that demand by closing the technology gap for them and giving them a level playing field so they can go head to head with top tier companies. Equally important, we keep making headway in moving a larger portion of our business toward recurring subscription revenue, especially in our AI enabled software offerings, which posted 25% year-over-year growth. In time, we believe this shift will bring even better revenue visibility while making our financial model more durable and predictable. Put together, these trends strengthen our confidence that the fundamentals underpinning our business stay very strong. In addition, during the second quarter, we rolled out 3 major product innovations that bolster our competitive position further while widening our long term opportunities at OptimizeRx. To start, we said that DeepIntent became the first health care demand side platform to connect directly with our authenticated EHR network. That marks a key milestone in our approach of making point-of-care media simpler to access via the programmatic platforms health care marketers already depend on. With media buying continuing to move toward programmatic workflows, we are establishing OptimizeRx as the trusted infrastructure that links premium point-of-care inventory to the industry's top buying platforms. The implementation is live now. Next, we rolled out our patent pending natural language audience builder, or NLAB; this AI powered tool lets pharmaceutical marketers and agencies create highly customized health care provider audiences with plain natural language prompts right inside DSPs and media planning platforms. Through pairing our proprietary health care intelligence with intuitive AI driven workflows, we are making it much easier for marketers to create targeted audiences while embedding OptimizeRx technology even deeper into the planning tools our customers already use today. Last, we introduced CopayQ, our next generation copay activation solution driven by real time prescribing intent. Affordability of medication is still 1 of the biggest obstacles to patient adherence, and CopayQ brings savings information straight into the prescribing workflow at the very moment physicians make treatment decisions. Through combining real time intense signals with our industry leading point-of-care and point-of-prescribe capabilities, we are assisting life science organizations in improving patient access while producing stronger commercial outcomes for their brands. On their own, each of these launches marks a major step forward for our platform. Together, they show something even bigger; that we have moved into a new phase of innovation as a company. We are changing from being only a point-of-care marketing company into the operating system for pharmaceutical marketers. Our technology infrastructure links pharmaceutical marketers media agencies, demand side platforms, health care providers, and patients at scale via authenticated clinical workflows. With artificial intelligence finding its way more and more into commercial planning, and with health care advertising steadily shifting toward programmatic execution that protects privacy, we think the mix we offer—our own health care data, authenticated clinical inventory, and workflow integration—amounts to a platform that stands apart, one with considerable potential for growth over the long term. This strategic progression widens the market we can serve, and it also opens up further recurring revenue possibilities that, in our view, will carry growing significance as time goes on. Ahead of handing the call to Edward, I want to pass along something important about leadership in our finance organization. Across close to 5 years serving as chief financial officer—spanning earlier duties as our Chief Operations Officer and, more recently, our chief strategy officer—Edward Stelmakh and the board of directors have reached a mutual agreement on a planned leadership transition that takes effect 12/31/2026; this speaks both to how much talent exists inside our organization and to our dedication to careful financial stewardship. Throughout the last 5 years, Edward has been pivotal in reshaping our financial foundation and in putting OptimizeRx in position for success over the long term.
Thanks to his guidance, our gross margins and operating margins have grown considerably. We've also tightened how we run the business, pulled off a refinancing of our debt that meaningfully lowered our cost of capital, finished buying and integrating Medicx, carried out the sale of noncore assets so our strategic focus is sharper, and assembled a strong, deeply skilled finance and strategy team that sets the company up nicely going forward. Equally important, Edward has been instrumental in creating the financial discipline and operational rigor that underpin our long term strategy and our pledge to create sustainable shareholder value. Through our long term succession planning process, we're happy to share that Andy D'Silva will take over from Edward as our chief financial officer starting 01/01/2027. Most recently, Andy was our chief business officer, and he has collaborated closely with Edward, the board of directors, and our executive leadership team on financial strategy, capital allocation, investor relations, corporate development, and long range planning. He has had a hand in a great many of the strategic initiatives that have helped reshape the business across the past several years, which leaves him well prepared to head our finance organization as CFO; we're also happy to share that Heather Favazza will move up to Chief Accounting Officer starting 01/01/2027. Heather has been a standout leader within our financial organization and was instrumental as our corporate controller across the last 8 years. She has strengthened our accounting operations, financial reporting, internal controls, and overall finance infrastructure. Her promotion speaks to both the strength of our accounting organization and the deep leadership bench we've assembled across the past several years. To make sure the handover is seamless, Edward will stay on as our chief financial and strategy officer through the end of 26; and he has also agreed to serve as strategic adviser in 2027, which gives ample time for a thoughtful and seamless transfer of responsibilities. It also lets Andy and Heather keep working closely with him as they step into their expanded leadership roles. Changes like this work best when they come from thoughtful planning instead of necessity; and that is precisely what this is. I have tremendous confidence in Andy and Heather, and we're just as grateful that Edward will keep supporting the company through the transition. On behalf of our board of directors and everyone at OptimizeRx, I want to thank Edward for his outstanding leadership and the many contributions he has made during his tenure. With that, I will turn the call over to Edward.
Thanks, Steve — that means a lot. There are definitely a lot of different feelings in the room right now, but I'd say I'm clear-headed, confident, and excited about where this business is headed. Over the back half of 2026, I'm looking forward to driving our strategic priorities ahead, and once we get to 2027, I'll be happy to serve the company's mission in an advisory capacity. I want to thank the board, our leadership team, everybody who works here, and all of our shareholders. Having had this amazing opportunity over these last five years is something I deeply value — it's truly been an honor to serve as chief financial and strategy officer, and I'm eager to see what comes next. Now let's turn to our financial results for Q2 '26. As always, our earnings release went out this afternoon. It details the second quarter's figures, and that quarter ended on 06/30/2026. A copy is available in the Investor Relations section of our website, and we'll also be filing our upcoming Form 10-Q, which will contain additional information. Second quarter revenue was $20.5 million. That represents a 30% decline from the $29.2 million recorded during the same quarter of 2025. The bulk of that decrease stemmed from a handful of large customers who, back in 2025, were utilizing our managed services offerings that carry lower margins. That's a line of business we've been exiting since our acquisition of Medicx in 2023. On top of that, a major client from 2025 generated zero revenue this quarter. Macroeconomic conditions, including MFN pricing dynamics, also weighed on demand. For the quarter ending 06/30/2026, our expenses declined by $5.4 million versus the prior-year period, finishing at $20.6 million, mainly driven by a reduction in cost of revenue. That came about even with $1.7 million of severance costs related to the workforce reduction we previously announced. The decrease in cost of revenue was primarily attributable to an improved product mix, given that we had no DTC managed service revenue this quarter, plus a more favorable mix of channel partners. We believe the margin optimization strategies we've implemented over the last 18 months continue to produce strong results. As a result, for the full year 2026, we project gross margins will return to a range between the high 60% and low 70%. Meanwhile, for the 3 months ended 06/30/2026, we posted a net loss of $700 thousand, which equals $0.04 per basic and diluted share. That's versus net income of $1.5 million, or $0.08 per basic and diluted share, for the comparable 3 month period in 2025. Non-GAAP net income for the second quarter of 2026 was $3.1 million, or $0.16 per diluted share. That compares with non-GAAP net income of $3.7 million, or $0.19 per diluted share, a year earlier. I should also mention that our cash position included $4.1 million, with $750,000 coming from the prior quarter's cost reductions. Looking at the second quarter of 2026, adjusted EBITDA landed at $4.9 million, compared with $5.8 million during the same period in 2025. Over the first six months of 2026, our business generated $8.1 million of cash, and we closed the quarter holding $24.1 million. On 12/31/2025, the comparable amount was $23.4 million. Back in May, we mentioned that Fifth Third Bank had refinanced the term loan we originally had with Blue Torch Capital; we pulled down the full $25 million term loan, and there's also a $10 million revolver available. Right now, the interest rate on that Fifth Third Bank term loan sits at SOFR plus 2.25%. With that said, we paid down $5.3 million of principal during the quarter, which was $5 million more than the scheduled amount, leaving $19.7 million of debt outstanding at the end of June. Beyond that, once the quarter closed we paid off an additional $3 million of debt. At this point, we intend to steer at least a portion of our free cash flow toward accelerating principal repayment, because reducing our cost of capital is always a goal; past that, we remain convinced that a solid balance sheet puts us in a strong position to hit our operational targets. Now let's go through our KPIs for Q2 2026. Average revenue per top 20 pharmaceutical manufacturer now stands at $2.7 million. Our net revenue retention rate dropped compared with earlier periods, coming in at 90%. Most of that decrease stemmed from a few large accounts cutting back their spending rather than broad-based churn. Additionally, revenue per FTE came to $750 thousand. Even with these KPIs down from prior quarters, we've made genuine headway on widening margins and keeping operating expenses in check. That's consistent with our approach of chasing profitable growth in our industry. Given our first-half results and what we can see for the remaining months, we're maintaining the 2026 full-year guidance we provided before. Revenue ought to still fall within $95 million to $100 million, while adjusted EBITDA ought to reach $21 million to $25 million. Although parts of health care marketing are still shifting, our performance so far this year, ongoing development of new products, a growing set of business from selected clients, and disciplined cost management give us confidence about the remainder of the year. As we've said before, we still anticipate the back half carrying a heavier share of revenue. That matches the purchasing patterns of many of our customers across the year, with the fourth quarter landing considerably higher than the third. We estimate that accounts for roughly 35% to 40% of our total annual revenue. So with that, I'll hand it back to Steve. Steve?
Thanks, Edward. Operator, let's now move to Q&A.
Hi, everybody. Dustin here, sitting in for Ryan on this call. Appreciate you taking our question. First off, I was curious whether there's anything new regarding that bigger customer you've mentioned before. I realize you likely can't share too many details, but at a broad level, what's the latest there, and what does the guidance for the second half assume when it comes to that customer? Thank you.
Hi, Dustin. Appreciate the question. At this moment, nothing is built into our second-half expectations regarding that big customer returning, though we're beginning to observe some momentum on that front, which will certainly have a favorable effect on the second half. By how much? We aren't ready to quantify that yet, but talks remain ongoing, and we're actively involved there. You might have noticed we just made an announcement about our chief marketing officer, and that chief marketing officer is joining us from that very customer; so my sense is he's positioned to help us close that gap and fix a few things where we stumbled, as we discussed during the prior quarter. Turning to the commercial side.
All right, that makes sense, and I appreciate the explanation. You mentioned how strategically important DSP is, so I was hoping you could share more about how things are going with DeepIntent and whether you're gaining any traction with the other DSPs in the market. I believe you also said that DSP might be able to double your business within the next 2 years. So what does that growth curve actually look like? For that DSP opportunity across the coming 24 months? Thank you.
Sure thing. The news on our end is really good. As of this past week, we've gone live with DeepIntent, which is a pretty exciting development for our company. We're beginning to observe bid flow moving across the platform. I don't think we're quite ready to describe what that uptick will look like, at least when it comes to the coming couple of weeks and months, though we do believe it will be very, very meaningful. I'd add that, when you look at the wider programmatic landscape right now, 60% of the buys taking place in this particular space are now happening via those programmatic channels. So when we talk about being able to scale the business through that ecosystem, that's tied directly to how many buys we know are flowing through these DSPs. And it isn't a place—those aren't funds we could reach before. We're broadening our near term accessible market, which gives you a bit more color behind that commentary; so there's more to come on that front; we are in conversations with additional DSPs. Still, there's nothing we're prepared to announce on this call. But stay tuned.
Understood. Thanks for the answer. Then, as a final item from our side: there's been talk involving the FDA and HHS about removing the adequate provision framework for pharma advertising. As you know, that would call for additional disclosures in DTC ads. What's your view on how that might affect the farmer marketing budgets and overall allocation? Might it cause some movement in TV and perhaps generate extra demand for your digital and point of care engagements? Thanks.
Sure. Happy to address that, Dustin. As you just suggested, we regard those developments as positive for our business. If anything restricts the capacity to run across other DTC channels where we might not have large-scale engagement, funds will naturally be redirected by us toward certain ACP focused marketing channels where we're connected and which are essentially our bread and butter; so we've been anticipating that with bated breath. We aren't putting it into our forecast since predicting what the FDA and HHS will or won't do is impossible for us. Even so, we're well positioned so that should they reach that decision, we'll benefit. It won't be only us; everyone in our space focused on HCP will disproportionately benefit us; so, great question.
Sure thing, thanks a lot.
Happy to help.
Thank you. When we examine the guidance you've provided for adjusted EBITDA, what it suggests is that for the second half, the figure would land in the range of $13 million to $17 million. Could you discuss, given that context, how your approach to capital allocation could begin to change? Is it still essentially all about paying down debt? Or might you consider a more even split between that and repurchasing shares, given how low the stock currently is?
Yes. Edward, I'll let you handle that one.
Absolutely. Richard, how’s it going? So, as we mentioned during the prepared remarks, our approach is going to be, first, to reduce the debt; we’ve gotten down to $16.7 million in outstanding principal; and second, should the stock price keep falling, we have a 10b5 to 1 ready to go that would trigger purchases. That’s with a $10 million stock buyback that’s been approved. Thank you.
And regarding the rebound in revenues during the second half that guidance implies, what portion of that is actually contracted and visible? Or what portion is essentially just a bet that the seasonal trends you've witnessed before will more or less recur?
Yeah. Well, Richard, to begin with, it's nice to hear from you; at this moment, as we mentioned on earlier calls, what we're observing is that things still lean more toward the seasonality of 24 contracted revenue rather than 25. That's simply where our progress stands; which explains why we're reaffirming the guidance currently in the market. Rather than raising it; we do believe the seasonal pattern from prior years is largely what we ought to expect for this year's back half. We're already beginning to observe that. Yet basically, the visibility we've provided is all we have, and it's what we've released. Whatever visibility exists for us; and anything extra beyond that, you know, clearly, on the upcoming earnings call, should we gain greater visibility into contracted revenue, we'd gladly give an update on it. But nothing is changing on that at present. We need to sort of resolve the 1 big client disruption we're dealing with and sort of examine what Q3 and Q4 will deliver before making any updates. Still, good — I would say strong, steady progress as we head toward the back half now.
Perhaps if we zoom out to what you'd describe as the top of the funnel, could you expand a bit on the non-top-20 opportunities, be they new logos or existing ones — how are those behaving, in contrast to the top 20, which have clearly run into things like MFN, and so on?
Yeah. They're expanding, and the pace of that expansion is picking up. That's what I believe we'd say to you. Several of the accounts beyond the top 20 rank among our fastest-growing 10, based on just the past couple of months. So that's something we're genuinely thrilled about. There will be additional news from us on this down the road, but the mid-tier long-tail approach is truly delivering, and the momentum we're witnessing there has us very excited; so there's a hole we need to close in 1 of those top accounts, the one where the disruption occurred, and filling it is going to require some time; yet between that account recovering and the mid tier, we believe we're heading into the latter portion of this year and positioning ourselves extremely well for 2027.
And finally from me, circling back to that top 20 group, leaving out the one difficult customer. Could you speak to what activity looks like in there — conversations, pipeline, fresh opportunities? How would you characterize that level of activity, in a non-quantifiable sense, compared with what things were like at the worst point of MFN?
Yeah. The level of activity has clearly gone up. I would say strategic conversations are beginning to move along much more freely than they did before. Early in the year, especially, I would say Q4 rolling into Q1 and, to some extent, a bit of Q2. And we have already covered this. There was a great deal of anxiety surrounding MFN. I think, as we discussed, everyone in our industry was talking about it. Simply because people weren't certain what to anticipate. I think by and large, manufacturers now find themselves in a position where they more or less understand what the new normal looks like, and they are ready for it. So we are beginning to observe engagement taking place across the board. Mid tier, long tail, engaging more quickly since they haven't truly been targets of the administration, and they have managed to kind of coast along and keep things business as usual and speed up and saw it almost as a moment to kind of leap ahead and compete more effectively with the top 20. So that has worked well for them. But we are beginning to see, in particular, folks within our top 10, 20, genuinely reengage in meaningful ways. I am not prepared to say yet that Q4 will be, you know, lightning in a bottle, you know, buy-ups like we discuss. Now and then that occurs. But we are receiving some genuinely positive buying signals heading into the back half of the year that look very good.
Appreciate the responses.
You're welcome. It's been good speaking with you, Richard. Hope we can reconnect before long. Thanks.
Yes. Regarding your remarks about most favored nation, it appears the disruption has been resolved. The remaining matters you mentioned, at least during the prior quarter, involved macroeconomic factors pressing on budgets — spanning inflation, oil, and geopolitical unpredictability. Does that continue to weigh on top 20 spending?
Hey, Eric. I appreciate the question; there is still somewhat of a lingering effect. I believe some unease persists regarding the macro picture; and pharma has ranked among 1 of the biggest targets of the administration, not only concerning MFN, but for a wide variety of causes. As a result, they have kept budgets somewhat cautious. But, once more, as I told Richard, much of that is beginning to settle down now during the back half. And they are beginning to allocate more broadly just to support patient capture for the latter portion of the year. And I believe we will gain from that. I do think — we never addressed LOE at all, but we are seeing a few distinct strategic developments occurring across the market at present. Possible acquisitions, certain mergers taking place, a handful of LOE events. So they will manage those matters. Yet on the whole, I believe the macro items we covered last quarter are beginning to normalize. In how they choose to spend.
To begin with, yeah. Alright. And on top of that, Edward, it was truly a pleasure collaborating with you. I'm aware that you're staying with us for an additional 5 months. And, Andy, congrats on the upcoming promotion. I wanted to inquire regarding operating expense. I realize you folks made a few — some cost adjustments during the second quarter. Has all of that concluded? Put differently, should we treat this as a normalized operating expense figure for the third quarter?
Yes. My view is that the present run rate for cash OpEx ought to remain roughly at this level. The sole thing that might shift would be items such as bonus accruals, which depend on what we start. Compared with budget. But broadly, I believe we'll land within that range.
Understood. Thanks.
Thank you. I have one about the business's margin profile. It appears that you have raised that outlook. So I suppose I have a few questions about that. First, can that level of profitability be sustained? Or is it instead a 2026 profile that you mean? That is number 1. Second, what caused the upside during the second quarter? I believe you mentioned channel mix, but I wanted to dig into that a bit further; and then the third item here, just your most current view on how profitability shifts as you add more while you move into the DSP market. Over time and, I suppose, more specifically, the economics of those arrangements. Versus traditional engagements.
Sure. Glad to jump in. It is nice to hear from you, Constantine. I appreciate the question. You know, I think we are establishing the business's new profitability level and making sure we communicate that clearly. It is not episodic. That truly will be the new normal. You will see we will likely beat that somewhat from time to time, but that ought to be, more or less, the baseline expectation for the business moving forward. And as we go into the, you know, macro DSP ecosystem, we do not anticipate that profitability will decline. It will hold at that same level that we are kind of guiding to and discussing right now. A favorable channel mix is driving most of that. As I have said on earlier calls, and Edward and Andy have as well, we have managed to bring on extra channel partners that have assisted us in managing our gross margin and therefore been, I think, transformational for the business; even with the disruption in top line revenue, we have kept generating good, solid EBITDA and cash flow and paying down the debt, all the things we have discussed on calls. We feel fairly bullish about profitability overall and about our capacity to keep generating cash and pay down the debt and do the things we would like to do; so provided we get the top line back in line, Constantine, like we discussed, and we all strongly believe we will. The, you know, the business's profitability will keep following suit; so but, yes, we are excited about that. Eddie, anything else you would add?
Oh, my apologies. Yes, let me tack on 1 brief point there. Right. So Constantine, as we view our operations, we truly run this company toward a gross margin in the high 60% range. Sure, we'll see some strong quarters, like the ones from the past 2 quarters that you noticed; still, that's the way we look at it on the inside. And that's the approach we'll take in running things. So when you're building out your models, please bear that sort of consideration in mind.
Understood. I don't want to dwell on this too much, but previously, you mentioned aiming to turn into a sustainable rule of 40 business. And Steve, plus, I suppose, Andy—all of you—I'm simply curious about your current perspective regarding whether that remains a goal. Do you believe that, you know, when you look forward, perhaps you might place a bit more emphasis on growth compared to what you thought before? Any sort of remarks on that would be useful. Thanks.
Yeah. That's fine. I mean, look. You go first, Edward.
Yes. Alright, thanks Steve. Yeah, I'd say without a doubt. The main reason being, well, this year is certainly somewhat unusual. As far as we're concerned, the bar for profitability has now been established. It's clear this business is capable of being very profitable even during a slow year. When growth comes back, and we're sure it definitely will in 2027, getting back to Rule of 40 won't require much at all. So from my perspective, without question, we'll be right back at it in 2027.
I'm ready to go. Appreciate it.
All right. Understood. Thank you, Constantine.
Thanks, operator. To wrap up today's call, I want to leave everyone with 3 points. To start, we keep carrying out our strategy as we turn in financial results marked by discipline. What we posted for the second quarter shows how sturdy our operating model is, and it shows our team can protect profitability even during years when headwinds blow, all while still putting money into innovation. Next, we see OptimizeRx as sitting in a one-of-a-kind spot where a number of strong long term forces converge, forces that are remaking how life sciences companies bring products to market. Those marketing health care increasingly want planning powered by AI, verified health care audiences, outcomes they can measure, and programmatic activation that runs across clinical workflows. For years we have been constructing the infrastructure needed to serve this turning point in the industry. When it comes to being the operating system for pharma marketers, nobody is better placed than us, thanks to the data driven technology we have created. Everything we announced this quarter, from our DeepIntent partnership through the debut of NLAB, which is our natural language audience builder, and CopayQ, illustrates how we put a culture of innovation first and keep widening our platform so it opens up more chances for sustainable recurring growth. Crucially, these innovations are not just standalone product launches. Taken as a whole, they make the network effects inside our platform even stronger, and they raise the value we hand to pharmaceutical manufacturers agency partners, health care providers, and in the end to patients. Third, we stay devoted to disciplined execution and to building shareholder value over the long term. What we prioritize has not changed. Keep growing what our AI enabled platform can do, boost usage of our proprietary HCP and DTC networks, speed up uptake of our recurring software solutions, widen programmatic access by way of more strategic partnerships, and produce profitable sustainable growth while keeping capital allocation disciplined, In our view, the money we have put in over the last several years has put OptimizeRx in a place to take advantage of the ongoing digital transformation happening throughout health care. The market environment could still see stretches of variability, yet our long term opportunity has never looked stronger. Being part of the OPRX story is thrilling right now. Before we finish, I want once more to acknowledge Edward for the incredible leadership and the contributions he has given OptimizeRx across the past 5 years. he has been a superb partner, a trusted adviser, and a leader who helped reshape our financial foundation while getting the company ready for its next stage of growth. From our Board, our employees, and our shareholders, Edward, thank you so much for all you have done for OptimizeRx. Last, I want to thank our employees for their unwavering commitment and execution. Our customers for their partnership and trust and our shareholders for their continued backing; we are grateful that you joined us today; and we look forward to bringing you up to date on how the quarter keeps progressing. Operator,, back to you.
Appreciate that, Mr. Silvestro. Before we close out the call today, I'd like to go through the safe harbor statement, since it includes important warnings regarding any forward-looking statements made during this call. Whatever management shares today may contain forward-looking statements, which fall under the definition given in Section 27A of the Securities Act of 1.93 thousand, as amended, along with Section 21B of the Securities Act of 1.93 thousand, as amended; you shouldn't make investment choices based on any of these forward-looking statements. Words like anticipate, estimate, expect, possible, and seeking, as well as expressions similar to them, indicate forward-looking statements. Statements of this kind speak only to conditions existing at the time they are uttered. During this call, we'll make forward-looking statements about several things: the smooth handoff of the finance chief role; how the business plans to grow and manage its finances, including ongoing improvements to margins, running operations with discipline, and the durability of its operating model; the fact that revenue slippage is limited to just a handful of major accounts; how new products are deepening customer involvement, boosting the company's standing against rivals, and widening long-term possibilities; the company's progress in becoming more profitable, reinforcing its balance sheet, growing its technology platforms, and opening up fresh paths for growth over the long haul. These statements also address the company's ability to hold onto significant competitive edges, as well as its push into mid-sized and emerging life sciences firms, which stands as 1 of the biggest opportunities that remain untapped. Our platform stands alone in its capacity to serve what customers need, our capacity to build a deeply differentiated offering with meaningful potential for growth over the long term, our approach of pursuing profitable expansion, our strong position to seize substantial opportunities, and our capacity to generate lasting value for shareholders. Outlooks shared by management regarding the remainder of the year likewise constitute forward-looking statements. We bear no duty to publicly refresh or amend any forward-looking statements, whether prompted by fresh information, later occurrences, or any other cause. Such statements involve risks and uncertainties by nature, and certain of these are impossible to foresee or measure. What we actually achieve down the road, along with what may happen or be suggested by these forward-looking statements, might end up being quite different. Among the risks and unknowns that bear on such statements are things like how government rules play out, competitive pressures, relying too heavily on a small set of clients, cyberattacks that might interfere with how we run things, our capacity to stay current as technology grows and shifts, whether we can hold onto agreements with e-prescribing services and EHR networks, plus various other significant hazards. Additional risks and uncertainties tied to forward-looking statements—ones that might impact our business and financial outcomes—are described in the company's Form 10-K annual report covering the year that closed on 12/31/2025, as well as in other documents the company has submitted and could submit later on with the SEC. After they're created, you can find these filings on the company's site as well as the SEC's site, www.sec.gov. Prior to wrapping up today's conference, I'd like to remind all of you that a recording of this call will be ready to replay beginning later tonight, and it will remain accessible for twelve months on the Investor Relations section of the company's website. Thank you for joining us on this call, and that concludes today's conference. You may now disconnect your lines.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete OptimizeRx Corporation transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to OptimizeRx Corporation earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.